NCT03381664View on ClinicalTrials.gov

Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 28, 2017

Primary Completion Date

January 30, 2018

Study Completion Date

January 30, 2018

Conditions
Healthy Adult Male and Female Volunteers
Interventions
DRUG

AVP-923

capsule

Trial Locations (1)

66212

Vince & Associates Clinical Research, Overland Park

Sponsors
All Listed Sponsors
lead

Avanir Pharmaceuticals

INDUSTRY